UroToday.com @urotoday Twitter profile

Last Seen Profiles

@WestieCapital

@ImRyanOakes

@Juliettejuljuju

@SriKGlobal

@Dr_Martha_psych

@BinorRaja

@stw_pdg

@n0ttomuch

@TheRealPCB_Live

@ChimeraMialst

@Vatsakhushii

@NFLDRAFTBLOG

@bahrozFTW

@Paul_NONAT

@jomitalca

@embarrassedolan

@dboeco

@ClariRiquelme_

@yiganorvanbash

@bokeplokalmalam

@Bel08038772

@RockyIbu

@MurielPleynet

@NexiiBuilds

@Johnykittyy_1

@doodhwaali

@jattali

@rich_saltzberg

@Fishtelizer

@gcsccommodores

@Yahoo

@c_cortijo15

@weasc

@takahas59112074

@BinorRaja

@KikiRoweMusic

UroToday.com

@urotoday

11 months

Incredible findings at #ESMO23 : Prostate radiotherapy significantly reduces the long-term risk of obstructive uropathy in #mHSPC . This supports the use of radiotherapy in men at risk of upper urinary tract obstruction. Presented by Craig Jones > @RKSayyid

0

54

94

UroToday.com

@urotoday

2 years

The role of community partnerships in advancing our understanding of #ProstateCancer disparities and improving patient outcomes. @SamWashUro @UCSFCancer & @yawnyame @UW joins @dr_coops @UCSF to discuss on UroToday >

0

13

82

UroToday.com

@urotoday

1 year

Potential cost savings based on the #MarkCuban #CostPlus Drug Company model. @RuchikaTalwarMD @VUMCurology joins @UroCancerMD @VUMC_Cancer to discuss the @JCO_ASCO publication looking at the @mcuban @costplusdrugs . #WatchNow > #HealthPolicy

10

16

66

UroToday.com

@urotoday

6 months

PSA persistence after radical prostatectomy: Optimal treatment in the case of PSA persistence. Presentation by @profnickjames @ICR_London . #EAU24 written coverage by @RKSayyid @UofT on UroToday > @Uroweb

0

18

58

UroToday.com

@urotoday

1 year

Unraveling the efficacy of PD-1/PDL-1 re-challenge in #KidneyCancer @DrChoueiri @DanaFarber_GU joins @CaPsurvivorship @DanaFarber in this discussion of the #CONTACT03 study on UroToday. 🧬🎯 > @TheLancet @montypal @AlbigesL @tompowles1 @crisuarez08

0

17

56

UroToday.com

@urotoday

4 years

The best sequence for M+ castrate-resistant #ProstateCancer in 2020. Presented by @AlisonBirtle @LancsHospitals . #EAU20 written coverage by @GoldbergHanan @UpstateNews on UroToday > @Uroweb

1

31

56

UroToday.com

@urotoday

3 years

Stereotactic ablative body radiotherapy for #KidneyCancer . Still experimental? Presentation by @_ShankarSiva @PeterMacCC . #ESOU22 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb

0

20

54

UroToday.com

@urotoday

4 years

Neoadjuvant vs adjuvant strategies in locally advanced #BladderCancer . Neoadjuvant strategies presented by @AndreaNecchi @IstTumori . #EMUC20 written coverage by @WallisCJD @VUMChealth on UroToday > @myESMO @Uroweb @ESTRO_RT

0

25

53

UroToday.com

@urotoday

5 months

Testosterone recovery after stopping ADT – who is at risk for long-term non-recovery? Presented by @PBlanchardMD @GustaveRoussy . #APCCC24 Written coverage by @zklaassen_md @GACancerCenter @mcg_urology . > @APCCC_Lugano

0

19

52

UroToday.com

@urotoday

5 years

"Mapping Progress in Bladder Cancer" This rapidly evolving landscape is incredibly exciting. @UroDocAsh @MDAndersonNews expands on the progress in bladder cancer & an explosion of clinical trials expanding our options. Full article by on UroToday now.

1

39

49

UroToday.com

@urotoday

4 years

VIRADS - Can we avoid TUR-B prior to radical cystectomy? Presentation by @VPanebiancoIT . #EMUC20 written coverage by @zklaassen_md @GACancerCenter on UroToday > @myESMO @ESTRO_RT @Uroweb

2

19

47

UroToday.com

@urotoday

4 years

Different #BladderCancer Genotypes: New treatment options. #EAU20 presentation by @Roland3097 @unibern . Written coverage by @GoldbergHanan @UpstateNews on UroToday > @Uroweb

1

29

46

UroToday.com

@urotoday

3 years

How MRI changed the #BladderCancer pathway: #NewEvidence . Presentation by @VPanebiancoIT @SapienzaRoma . #ESOU21 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb

0

16

45

UroToday.com

@urotoday

2 years

State of the Art Lecture: Synchronous vs metachronous #mHSPC : What makes the difference? Presentation by @ChrisSweens1 @DanaFarber . #EAU22 written coverage by @rksayyid @UofTUrology > @Uroweb

0

18

45

UroToday.com

@urotoday

3 years

There is no role for radical cystectomy in cT0 after neoadjuvant chemotherapy. Presentation by @amassonlecomte @HopSaintLouis . #EAU21 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb

0

15

45

UroToday.com

@urotoday

5 months

How to identify aggressive variant prostate cancer? Presented by Himisha Beltran, MD, @DanaFarber @harvardmed . #APCCC24 Written coverage by @RKSayyid @UofTUrology @ihpmeuoft . > @APCCC_Lugano

0

17

43

UroToday.com

@urotoday

2 years

SunRISe-4: TAR-200 + cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with #MIBC ineligible for or refuse neoadjuvant platinum-based chemotherapy. Presented by @spsutkaMD @fredhutch . @ASCO #GU23 written coverage by @WallisCJD @UofT >

2

6

43

UroToday.com

@urotoday

6 years

TODAY UroToday is celebrating 15 years online! Stay tuned for how we are celebrating!! @CaPsurvivorship @charlesryanmd @UroDocAsh @PhillipKooMD @Daniel_J_George @montypal @DrDianeNewman ( @PennUrology ) @PelvicMedicine @wandering_gu @uretericbud @PGrivasMDPhD @jaimelandmanuci

3

10

43

UroToday.com

@urotoday

6 months

Pelvic lymph node dissection in #ProstateCancer : Update of the limited vs. extended randomized clinical trial. Presented by @TouijerKarim @MSKCancerCenter . #EAU24 written coverage by @rksayyid , MD, MSc @UofT > @Uroweb

1

15

43

UroToday.com

@urotoday

5 months

Is digital rectal examination for the definition of local T-stage still appropriate in the time of MRI and next-generation imaging? Presentation by @declangmurphy @PeterMacCC . #APCCC24 written coverage by @RKSayyid @UofT > @APCCC_Lugano

1

20

43

UroToday.com

@urotoday

5 months

#MoonRISe -1: Phase 3 study of #TAR210 , an erdafitinib intravesical delivery system, vs intravesical chemotherapy in patients with IR #NMIBC with susceptible FGFR alterations. Presentation by @UrogerliMD @MoffittNews . #AUA24 coverage by @zklaassen_md >

1

16

42

UroToday.com

@urotoday

4 years

Molecular sub-staging of #BladderCancer : Is it really useful? Presentation by @pcvblack @VanProstateCtr . #EMUC20 written coverage by @WallisCJD @VUMChealth on UroToday > @myESMO @Uroweb @ESTRO_RT

1

16

41

UroToday.com

@urotoday

3 years

The role of radiotherapy for patients with node-positive locally advanced #ProstateCancer . Presentation by @PCaParker @royalmarsdenNHS . #ESMO21 written coverage by @WallisCJD @UofT on UroToday > @myESMO

0

24

42

UroToday.com

@urotoday

1 year

En bloc resection vs standard resection for bladder tumors: multicenter trial results and clinical considerations. This study showed a significantly lower 1-year recurrence rate with en bloc resection in #NMIBC . @jteoh_hk & @drtanws discuss on UroToday >

3

6

42

UroToday.com

@urotoday

11 months

Unveiling the treatment landscape for #mCRPC in #NorthAmerica ! What's the current state of #ProstateCancer care? Read this insightful review by @RKSayyid @UofT & @zklaassen_md @GACancerCenter on UroToday >

0

17

41

UroToday.com

@urotoday

4 years

Optimal first-line therapy in metastatic disease. Presentation by @MattGalsky @TischCancer . #EMUC20 written coverage by @WallisCJD @VUMChealth on UroToday > @myESMO @ESTRO_RT @Uroweb

0

14

40

UroToday.com

@urotoday

3 years

Avelumab combined with stereotactic ablative body radiotherapy in #mCRPC : The phase 2 ICE-PAC clinical trial. #BeyondTheAbstract with @EdmondMKwan , @SpainLavinia , Angelyn Anton, @DrBenTran , @_ShankarSiva , and @AzadOncology on UroToday > @EUplatinum

3

13

39

UroToday.com

@urotoday

3 years

Metastasis-directed therapy for oligorecurrent #ProstateCancer : a pooled analysis of prospective trials. Presented by @piet_ost @ugent . #EUA21 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb @declangmurphy @r_glicksman @matthewdeek

1

20

38

UroToday.com

@urotoday

4 years

What is changing in advanced #ProstateCancer ? #EverydayUrology #Journal article. @WallisCJD and @zklaassen_md "review the evidence underpinning recent changes in the management of patients with mCRPC, mCSPC, and nmCRPC." #ReadNow on UroToday >

0

22

38

UroToday.com

@urotoday

2 years

Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic #ProstateCancer ( #EXTEND ): A multicenter, randomized phase II trial. Presented by @ChadTangMD @MDAndersonNews . #ASTRO22 written coverage by @rksayyid > @ASTRO_org

0

8

37

UroToday.com

@urotoday

7 months

#ProstateCancer case studies: Localized, salvage radiotherapy/BCR, #mHSPC , and #mCRPC . A panel discussion led by @DrRanaMcKay along with @TDorffOnc , @AmarUKishan , Arash Kalebasty, MD, and @jgong15 . #SoCalGU24 written coverage by @zklaassen_md >

0

18

37

UroToday.com

@urotoday

6 months

Darolutamide, enzalutamide, and apalutamide for #nmCRPC patients in the #UnitedStates #DEAR : Comparative real-world evidence. Presentation by @zklaassen_md @GACancerCenter . #SESAUA2024 written coverage by @RKSayyid @UofT > @SES_AUA #SESAUA24

0

16

37

UroToday.com

@urotoday

2 years

Metastatic #ProstateCancer : Possible synergies between radioligand and systemic treatment in M1 prostate cancer? Future perspectives. Presentation by @ProfKHerrmann @unidue . #EAU22 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb

0

13

37

UroToday.com

@urotoday

4 years

Evolving Landscape for Frontline Treatment in Clear Cell Metastatic Renal Cell Carcinoma. @PGrivasMDPhD @fredhutch is joined by @DrChoueiri @DanaFarber , and @montypal @cityofhope highlighting the #CLEAR study in this conversation on UroToday > @UW

0

8

37

UroToday.com

@urotoday

6 years

#InternationalWomensDay celebrate ALL women in urology @CaPsurvivorship @sgkssg @cnsternberg @apolo_andrea @Tiahigano @loreleimucci @mishabeltran @SigridCarlsson @LoebStacy M.Hussain @NM_Urology @DrDianeNewman @Meg_McNamaraMD @TiansterZhang @mdesantis234 @pezaro_c @HalaBorno

4

7

36

UroToday.com

@urotoday

4 years

PSMA PET for upfront staging in high-risk disease. Presentation by @declangmurphy @PeterMacCC . #EMUC20 written coverage by @zklaassen_md @GACancerCenter on UroToday > @myESMO @Uroweb @ESTRO_RT

0

18

36

UroToday.com

@urotoday

2 years

Theranostics in #ProstateCancer management - The #TheraP trial. @DrMHofman @PeterMacCC joins @dr_coops @UCSFCancer to discuss areas of development in the diagnostic and theranostic spaces in prostate cancer management. #WatchNow > @PCFA

0

8

36

UroToday.com

@urotoday

3 years

Neoadjuvant treatments before radical prostatectomy for high-risk #ProstateCancer : Developments and challenges. Presented by Mary-Ellen Taplin, MD @DanaFarber . #ESOU22 written coverage by @zklaassen_md @GACancerCenter . #ReadNow > @Uroweb

1

19

35

UroToday.com

@urotoday

8 months

Salvage radiotherapy options for biochemical recurrence after local treatment. Presentation by @a_dalpra @SylvesterCancer . #GU24 written coverage by @zklaassen_md @GACancerCenter on UroToday > @ASCO

0

18

36

UroToday.com

@urotoday

3 years

Robotic transperitoneal and retroperitoneal approach: When and how? Presentation by @NNHarke . #ESOU22 written coverage by @WallisCJD @UofT on UroToday > @Uroweb

0

8

36

UroToday.com

@urotoday

1 year

225-Actinium-PSMA-617: Data and perspectives from a #MedicalOncologist . Presentation by Megan Crumbaker, @SVHSydney . Written coverage by @zklaassen_md @GACancerCenter on UroToday > @pros_tic @PCF_Science @PCFnews @PeterMacCC @gu_onc

1

12

36

UroToday.com

@urotoday

5 years

Cytoreductive nephrectomy for metastatic renal cell carcinoma #mRCC treated with immune checkpoint inhibitors or targeted therapy. @ASCO #GU20 presentation by @ZiadBakouny @DanaFarber . Written coverage by @jberchuck on UroToday >

0

15

35

UroToday.com

@urotoday

4 years

Molecular landscape of non-muscle-invasive #BladderCancer and subcellular risk factors for progression. Presentation by @eugene_pietzak @sloan_kettering . #GU21 written coverage by @zklaassen_md @GACancerCenter on UroToday > #ASCOGU @ASCO

1

11

35

UroToday.com

@urotoday

1 year

Combination Therapies Come of Age in #KidneyCancer . Presentation by @BraunMDPhD @YaleCancer . #ASCO23 written coverage by @zklaassen_md @GACancerCenter > @ASCO

1

22

34

UroToday.com

@urotoday

6 months

No need for TURBT, VI-RADS makes the diagnosis. Presentation by @VPanebiancoIT @unirome1 . #EAU24 written coverage by @RKSayyid @UofT > @Uroweb

1

21

34

UroToday.com

@urotoday

2 months

The triangle offense: Harnessing NK cells, T-cells, and memory cells in #BladderCancer . @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss this groundbreaking approach for bladder cancer but potentially for other cancers as well >

1

10

35

UroToday.com

@urotoday

2 years

Metastatic #ProstateCancer : Treatment landscape of castrate resistant M1 p prostate cancer. Presentation by @Ecastromarcos . #EAU22 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb

0

13

35

UroToday.com

@urotoday

1 year

The impact of surgeon experience and volume on patient outcomes in radical prostatectomy patients. #LibraryResource @zklaassen_md @GACancerCenter and @RKSayyid @UofT highlight current evidence on UroToday >

0

12

34

UroToday.com

@urotoday

1 month

The triangle offense: Harnessing NK cells, T-cells, and memory cells in #BladderCancer . @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss this groundbreaking approach for bladder cancer but potentially for other cancers as well >

2

5

36

UroToday.com

@urotoday

3 years

#Urologists , You’ll never walk alone! How novel immunotherapy and modern imaging may change the management of #NMIBC . #BeyondTheAbstract > @GGiannarini @neerajaiims @apolo_andrea @AndreaNecchi @albertobrigant1 @PGrivasMDPhD @shilpaonc @UroDocAsh

1

16

34

UroToday.com

@urotoday

6 months

Options and challenges in the management of oligometastatic #ProstateCancer in the PSMA-PET era. Presentation by @ChrisSweens1 @UniofAdelaide . #EAU24 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb

2

16

34

UroToday.com

@urotoday

4 years

Nivolumab + cabozantinib vs sunitinib in 1st line treatment for advanced #RenalCellCarcinoma : first results from the randomized phase 3 #CheckMate9ER trial. Presented by @DrChoueiri @DanaFarber . #ESMO20 written coverage by @WallisCJD @VUMChealth > @myESMO

0

17

33

UroToday.com

@urotoday

4 years

The dynamic advancements in personalized treatments for metastatic #UrothelialCancer . @apolo_andrea @theNCI joins @UroDocAsh @MDAndersonNews reviewing new arrivals in the therapeutic options for the management of metastatic bladder cancer. #WatchNow >

2

11

34

UroToday.com

@urotoday

4 years

Treatment of recurrent lymph node metastatic #ProstateCancer - Radiation is the best option. #EAU20 presentation by @piet_ost @ugent . Written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb

0

19

34

UroToday.com

@urotoday

3 years

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant #ProstateCancer #VISION . Great presentation by @morr316 @sloan_kettering ! #ASCO21 written coverage by @WallisCJD @VUMCurology on UroToday > @asco

0

18

33

UroToday.com

@urotoday

6 years

We have reached #10000followers and were able to celebrate with some of our friends at #LUGPA #10YrsLUGPA @UroDocAsh @CaPsurvivorship @urokaul @DianeNe52688743 @PhillipKooMD @UrologyUS

2

3

32

UroToday.com

@urotoday

8 months

Setting the stage: Biochemical recurrence after local treatment for #ProstateCancer . Presentation by @Tilki_De @MartiniKlinik . #GU24 written coverage by @zklaassen_md @GACancerCenter on UroToday > @ASCO

0

12

32

UroToday.com

@urotoday

2 years

Triplet therapy with cabozantinib, nivolumab, and ipilimumab as first-line treatment in patients with advanced #RenalCellCarcinoma . @DrChoueiri joins @CaPsurvivorship in discussing the #COSMIC313 study on UroToday > @DanaFarber

0

8

32

UroToday.com

@urotoday

4 months

ARV-766, a #PROTAC androgen receptor degrader, in #mCRPC : Initial results of a phase 1/2 study. Presentation by @DanielPetrylak @YaleCancer . #ASCO24 written coverage by @zklaassen_md @GACancerCenter > @ASCO

1

15

33

UroToday.com

@urotoday

2 months

QUILT-2.005: Comparing BCG + IL-15 superagonist N-803 vs BCG alone in BCG-naïve #NMIBC . Bobby Reddy, MD @ImmunityBio joins @UroCancerMD @VUMCurology to discuss the results from the QUILT 2.005 trial, showing high durability and response rates in patients >

1

7

33

UroToday.com

@urotoday

8 months

Apalutamide and SBRT for low-burden, metastatic, hormone-sensitive #ProstateCancer #PERSIAN . Presentation by @GiulioFrancoli1 @AOUCareggi . #GU24 written coverage by @RKSayyid @UofT > @ASCO

0

14

32

UroToday.com

@urotoday

6 months

PSMA-PET guided intensification of salvage radiotherapy after radical prostatectomy: a phase 2 randomized controlled trial. Presentation by Colin Belliveau, MD @chumontreal . #EAU24 written coverage by @RKSayyid @UofT > @Uroweb

2

19

33

UroToday.com

@urotoday

3 years

En bloc resection in non-muscle invasive #BladderCancer #NMIBC : Where do we stand? Presentation by @AlbertoBreda1 @FPuigvert . #ESOU22 written coverage by @zklaassen_md @GACancerCenter . #ReadNow on UroToday > @Uroweb

3

9

33

UroToday.com

@urotoday

2 years

#ARNEO : a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk #ProstateCancer . Presentation by @joniau @UZLeuven . #EAU22 written coverage by @zklaassen_md @GACancerCenter > @Uroweb

0

13

32

UroToday.com

@urotoday

3 years

The impact of #Decipher biopsy testing on clinical outcomes in localized #ProstateCancer . @randy_vincejr @UMRogelCancer joins @DrSpratticus @cwru discuss recent work in this conversation on UroToday > @Decipher_VCYT @Veracyte

0

6

32

UroToday.com

@urotoday

8 months

Exciting insights from @ASCO #GU24 ! Dr. @JoshMeeks addressed the BCG shortage in #UrothelialCarcinoma and explored future alternatives. Written coverage by @zklaassen_md @GACancerCenter on UroToday >

0

14

32

UroToday.com

@urotoday

4 years

Cabozantinib in combination with atezolizumab as first-line therapy for advanced clear cell #RCC : Results from the #COSMIC021 study. Presentation by @montypal @cityofhope . #ESMO20 written coverage by @zklaassen_md @GACancerCenter on UroToday > @myESMO

0

8

31

UroToday.com

@urotoday

3 years

Do we need the second PET (FDG) for patient selection? (including SUV for selection of PSMA therapy). Presentation by @DrMHofman @PeterMacCC . #APCCC21 written coverage by @WallisCJD @UofT on UroToday > @APCCC_Lugano

0

16

31

UroToday.com

@urotoday

4 years

Beyond #BladderCancer : #BCG vaccination trial (BACTIR) to reduce #COVID19 related adverse events in high-risk health care workers and the elderly. #ReadNow > @VikramNarayan @UroDocAsh @MDAndersonNews @GGiannarini @bcan_chisolm @BladderCancerUS

1

23

32

UroToday.com

@urotoday

5 months

Novel targets and treatment developments in metastatic hormone-sensitive #ProstateCancer . @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss on UroToday >

0

11

31

UroToday.com

@urotoday

2 years

Duration of androgen suppression with post-operative radiotherapy #DADSPORT : a collaborative meta-analysis of aggregate data. Presentation by Sarah Burdett @MRCCTU . #ESMO22 written coverage by @zklaassen_md @GACancerCenter > @myESMO

0

21

31

UroToday.com

@urotoday

4 years

#TheraP : 177Lu-PSMA617 theranostic vs Cabazitaxel in progressive metastatic castration-resistant #ProstateCancer . @DrMHofman @PeterMacCC & @Prof_IanD @MonashUni join @CaPsurvivorship @NUFeinbergMed discuss trial date presented at #ASCO20 . > @ANZUPtrials

0

12

31

UroToday.com

@urotoday

2 years

The current landscape of metastatic hormone-sensitive #ProstateCancer : A plethora of treatment options. #LibraryResource @zklaassen_md , @rksayyid , and @WallisCJD discuss doublet, triplet, and radiotherapy treatment options on UroToday > #mHSPC

1

15

30

UroToday.com

@urotoday

4 years

Nonmuscle-invasive #BladderCancer : overcoming diagnostic and therapeutic challenges. @pjhensley11 and @UroDocAsh @MDAndersonNews discuss current challenges, emerging diagnostic approaches, and advances in intravesical and systemic therapy. #ReadNow >

0

16

31

UroToday.com

@urotoday

1 year

Quality of life in #BladderCancer : a comparative study on cystectomy vs bladder preservation. @VedangMurthy @TataMemorial joins @PhillipKooMD @BannerHealth to discuss his study and the implications on UroToday. > @ASTRO_org

1

8

30

UroToday.com

@urotoday

3 years

Conditional survival and 5-year follow-up in #CheckMate214 : first-line nivolumab + ipilimumab vs sunitinib in advanced #RCC . Presentation by @motzermd @sloan_kettering . #ESMO21 written coverage by @zklaassen_md @GACancerCenter on UroToday > @myESMO

1

15

30

UroToday.com

@urotoday

2 years

Are there predictors for successful treatment of oligometastatic #ProstateCancer ? Presentation by @piet_ost @ugent . #APCCC22 written coverage by @WallisCJD @UofT on UroToday > @APCCC_Lugano

0

11

30

UroToday.com

@urotoday

5 months

#RadiationOncology for #RCC : Localized disease, oligometastatic disease, and the future. Presented by @l_ballas @CedarsSinai . #AUA24 written coverage by @chavarriagaj @UofT > @AmerUrological

0

14

30

UroToday.com

@urotoday

5 years

Radiation therapy advances and technology overview. @DrSpratticus @UMRogelCancer presents on the practical aspects of the technological evolution in radiation therapy at #LUGPA19 . #WatchNow on UroToday > @UrologyUS Discussant: Constantine Mantz, MD

1

12

29

UroToday.com

@urotoday

1 year

Enhancing patient-centered communication in small renal mass management. @kategessner_uro @UNCUroOnc joins @RuchikaTalwarMD @VUMCurology to discuss the Grade SRM #ClinicalTrial and explore decisional conflicts due to multiple management options >

1

9

30

UroToday.com

@urotoday

1 year

First results from #SunRISe -1 in patients with BCG unresponsive high-risk #NMIBC receiving TAR-200 in combination with cetrelimab, TAR-200, or cetrelimab alone. Presented by @siadaneshmand @KeckMedUSC . #AUA23 written coverage by @rksayyid @UofT >

0

9

29

UroToday.com

@urotoday

1 year

The role of cytoreductive nephrectomy and surgical Metastatectomy. Presentation by Shawn Dason, MD @OSUCCC_James . #ASCO23 written coverage by @RKSayyid @UofT > @ASCO

0

9

29

UroToday.com

@urotoday

4 years

Updated outcomes of #POUT : a phase III randomized trial of peri-operative chemotherapy vs surveillance in upper tract #UrothelialCancer . Presentation by @AlisonBirtle . #GU21 written coverage by @zklaassen_md @GACancerCenter on UroToday > @RosemereCF @ASCO

1

14

29

UroToday.com

@urotoday

3 years

Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle-invasive #BladderCancer . Presentation by Alexandre Zlotta, MD, PhD @MountSinaiNYC . #GU22 written coverage by @WallisCJD @UofT on UroToday > @ASCO @neerajaiims

2

8

29

UroToday.com

@urotoday

3 years

An AI-derived digital pathology-based biomarker to predict the benefit of ADT in localized #ProstateCancer with validation in NRG/RTOG 9408. Presented by @DrSpratticus . #GU22 coverage by @zklaassen_md > @UHhospitals @ASCO @felixfengmd @AarmstrongDuke

0

10

29

UroToday.com

@urotoday

10 months

Androgen receptor agonist versus antagonist: cardiac morbidity. Great presentation from @CaPsurvivorship @DanaFarber . #SUO23 written coverage by @RKSayyid @UofT on UroToday > @UroOnc #SUO2023

1

9

28

UroToday.com

@urotoday

4 years

Oncologic outcomes of Mohs surgery for localized #PenileCarcinoma : A 10-year retrospective study presented by Nicolas Alcalá @UNC . #SUO20 written coverage by @zklaassen_md @GACancerCenter on UroToday > @UroOnc @SUO_YUO

0

3

29

UroToday.com

@urotoday

11 days

Radioligand theranostics in #ProstateCancer : Status quo and new developments. Presentation by @ProfKHerrmann . #ESMO24 written coverage by @zklaassen_md > @myESMO

1

13

30

UroToday.com

@urotoday

3 years

A phase III trial of docetaxel vs docetaxel and radium-223 in patients with #mCRPC #DORA . Presentation by @morr316 @sloan_kettering . #ASCO21 written coverage by @zklaassen_md @GACancerCenter on UroToday > @ASCO @DrScottTagawa @Tiahigano

0

14

28

UroToday.com

@urotoday

5 months

How to manage patients with PSA persistence following radical prostatectomy? Presentation by @Tilki_De @MartiniKlinik . #APCCC24 written coverage by @zklaassen_md @GACancerCenter > @APCCC_Lugano

0

18

29

UroToday.com

@urotoday

3 years

Diagnostic performance of Ga-68 PSMA PET/CT #Imaging in early-relapsed #ProstateCancer : phase 3, prospective, multicenter study (IAEA-PSMA study). Presentation by Juliano Cerci, MD, PhD. #ASCO21 written coverage by @zklaassen_md > @ASCO @stefanofanti4

0

10

29

UroToday.com

@urotoday

4 years

Oligometastatic disease in genitourinary cancers: definition and biology. @hvdpoel @NKI_nl . #EMUC20 written coverage by @zklaassen_md @GACancerCenter > @myESMO @Uroweb @ESTRO_RT

0

10

29

UroToday.com

@urotoday

1 year

PSMA PET findings in an “EMBARK-like” cohort of pts with high-risk #nmHSPC : a single center posthoc retrospective analysis. Presented by Wesley Armstrong @uclacaltechmstp . #ASCO23 written coverage by @zklaassen_md @GACancerCenter > @ASCO

1

18

28

UroToday.com

@urotoday

3 years

Financial toxicity in #BladderCancer - A mixed-methods study of two diverse patient populations. @SumeetBhanvadia @USC_Urology joins @UroDocAsh @MDAndersonNews to speak about the burden and impact of financial toxicity amongst bladder cancer patients >

0

8

28

UroToday.com

@urotoday

2 years

Biological pathways in #UrothelialCarcinoma . @CChuMD @UrologyMSK joins @UroCancerMD @VUMCurology discussing data on genetic changes and alterations in urothelial carcinoma. #WatchNow on UroToday >

0

12

28

UroToday.com

@urotoday

6 months

Comparison of biparametric and multiparametric MRI for #ProstateCancer detection: The #PRIME study. Presentation by @veerukasi @ucl . #EAU24 written coverage by @zklaassen_md @GACancerCenter > @Uroweb

0

16

28

UroToday.com

@urotoday

5 months

Updates on metastasis-directed therapy. Presentation by @angela_jia_ @RadOncUH . #AUA24 written coverage by @RKSayyid @UofT > @AmerUrological

0

14

28

UroToday.com

@urotoday

2 years

How should PET-detected oligorecurrent #ProstateCancer best be treated? @ChrisSweens1 @DanaFarber presents in favor of systemic therapy. #EAU22 written coverage by @rksayyid @UofTUrology on UroToday > @Uroweb

0

14

28

UroToday.com

@urotoday

2 years

PARP Inhibitors in #mCRPC . @Ecastromarcos joins @CaPsurvivorship to discuss the use of #PARPInhibitors and their combinations in advanced #ProstateCancer , sharing insights from the TRITON3, TALAPRO-2, and PROpel studies. #StayInformed with UroToday >

0

7

28

UroToday.com

@urotoday

8 months

Evaluation of the primary tumor with PSMA PET: time impact of the #PRIMARY trial. Presented by @drlouiseemmett . Written coverage of the #2024PSMAConference by @zklaassen_md on UroToday > @PSMAconference @UCSFCancer @UCLAJCCC @PCFnews

0

12

28